Prophylactic Bilateral Salpingectomy as a Prevention Strategy in Women at High-Risk of Ovarian Cancer: A Mini-Review by Tess Schenberg & Gillian Mitchell
MINI REVIEW ARTICLE
published: 10 February 2014
doi: 10.3389/fonc.2014.00021
Prophylactic bilateral salpingectomy as a prevention
strategy in women at high-risk of ovarian cancer: a
mini-review
Tess Schenberg1 and Gillian Mitchell 2,3*
1 TheWestern Health Public Hospital, Melbourne, VIC, Australia
2 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
3 Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
Edited by:
Viive Maarika Howell, University of
Sydney, Australia
Reviewed by:
Tamara Louise Kalir, Mount Sinai
School of Medicine, USA
Janice Kwon, The University of British
Columbia, Canada
*Correspondence:
Gillian Mitchell , Familial Cancer
Centre, Peter MacCallum Cancer
Centre, Locked Bag 1, A’Beckett
Street, Melbourne, VIC 8006,
Australia
e-mail: gillian.mitchell@petermac.org
Risk-reducing bilateral salpingo-oophorectomy is a proven strategy to reduce the risk of
serous ovarian cancer associated with germline BRCAmutations. It is most effective when
performed before natural menopause, but it will render a woman prematurely menopausal.
The tubal hypothesis of serous ovarian cancer brings with it the possibility of the alternative
surgical approach in younger women comprising of risk-reducing bilateral salpingectomy
while conserving their ovaries until nearer the age of natural menopause, when a delayed
bilateral oophorectomy can be performed. This article will review the evidence behind the
tubal hypothesis of serous ovarian cancer and explore the opportunities for translating this
into clinical cancer prevention practice.
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Women at a high-risk of developing serous ovarian cancer due to
their inheritance of a germline mutation in a cancer predisposition
gene, such as BRCA1, BRCA2 (1), are strongly advised to have pro-
phylactic surgery to remove their ovaries and fallopian tubes (risk-
reducing bilateral salpingo-oophorectomy RRBS0) once child-
bearing is complete (2,3). Screening for ovarian cancer in high-risk
populations is not recommended although a recent report sug-
gests a degree of tumor down-staging with a strict adherence to
an intensive screening protocol (4). No mortality benefit has been
shown for ovarian cancer screening, even with strict adherence to
screening protocols, in contrast to a clear mortality reduction with
RRBSO in this population (5). Premenopausal BSO also brings a
50% reduction in breast cancer incidence in this high-risk group
(5) reinforcing the recommendation for early RRBSO.
The timing of an RRBSO is crucial as the stakes are high. On
one hand there is the risk of death from cancer, but this needs to
be balanced by the potential for significant morbidity and occa-
sional mortality as a consequence of the procedure itself. These are
often young patients without cancer and if guided to the wrong
prophylactic strategy, they could develop invasive and potentially
incurable cancer. However, the risks of the procedure itself also
need to be considered, including the immediate surgical and anes-
thetic risks but also the medical and psychological complications
of plunging a woman into a premature menopause.
RRBSO can be a morbid procedure, particularly for younger
premenopausal women, although the majority report a positive
outcome overall (6–8). In the non-high-risk population, a bilat-
eral oophorectomy at a younger age is associated with increased
all-cause mortality (9, 10), predominantly related to the increased
risk of cardiovascular disease (11). Reportedly, there is also an
increased risk of Parkinsonism, cognitive impairment or dementia
(12–14), and osteoporosis (15). While there are good prospec-
tive data to support a short-term improvement in mortality for
RRBSO in high-risk women (5), the very long-term effects on mor-
bidity and mortality in this group are unknown (6). Obviously,
any option to prevent women experiencing an early menopause
is going to be attractive to both clinicians and patients. Since the
tubal hypothesis of ovarian cancer was first published in 2007 (16),
there has been increasing discussion about a staged approach of
initial bilateral salpingectomy (RRBS) once childbearing is com-
plete, followed by a delayed oophorectomy (RRBO) closer to
natural menopause (17–19).
Prior to 2001, the hypothesis underlying the pathogenesis of
ovarian cancer implicated the ovarian surface epithelium or cor-
tical epithelial inclusions that occur during ovulation, with the
different ovarian cancer subtypes due to cellular metaplasia. Once
initiated the ovarian cancer would then spread to the fallopian
tube and other gynecological organs and the wider pelvic and
abdominal cavities. In 2001, reports of a high rate of tubal neo-
plastic lesions in the RRBSO specimens from high-risk women
were published (20, 21). In these reports, fallopian tubes of high-
risk women were carefully examined and preinvasive cancerous
lesions were found leading to other reports with similar findings
(22, 23) and the unifying hypothesis by Crum et al. suggesting that
the fallopian tubes were the site of origin of many serous ovarian
cancers (16). These precursor lesions – tubal intraepithelial carci-
nomas (TICs) – had no correlating precursor lesions within the
ovary. When specimens from women with serous ovarian cancers,
untested for BRCA mutations, were examined these lesions were
also found in at least 40–60% of cases and the fimbrial end of
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the fallopian tube obliterated in another 20% (24, 25). Further
support of the tubal origin hypothesis came from the highly simi-
lar cytological features and striking molecular similarities between
TICs and invasive high grade ovarian cancers (25). These include
identical TP53 mutations, a high proliferation rate, chromosomal
instability, and gene expression profiles, which all support a clonal
origin (26–28).
A refinement to the tubal hypothesis is that the fimbrial ends
of the tubes appear to be most vulnerable to malignant trans-
formation, which may explain why tubal ligation provides some
ovarian cancer protection in BRCA mutation carriers as well as
women in the general population (29). In 2006, researchers from
Boston described a protocol for sectioning and extensively examin-
ing the fimbrial end of the fallopian tubes (SEE-FIM). The fimbria
were an area of interest as they are exposed to the peritoneal cav-
ity, are in close proximity to the ovarian surface, merge with the
serosal mesothelium, and often contain transitional metaplasia
(26). It was found, and subsequently confirmed by others using
the same sectioning technique, that the fimbria were the most
common place for precancerous and non-invasive malignant pre-
cursor lesions within the fallopian tubes (26, 30, 31). Molecular
analyses confirm these observations; within the non-neoplastic
mucosa of the distal tubes was a benign precursor entity consist-
ing of foci of strong p53 immunostaining (indicative of a TP53
mutation), subsequently termed the “p53 signature.” The p53 sig-
nature was equally common in non-neoplastic tubes from BRCA
mutation carriers and controls, but was observed more frequently
and was multifocal in fallopian tubes that also contained TIC. Like
the prior studies of TIC, p53 signatures predominated in the fim-
briae (23, 30). However, despite the predilection for the fimbriae,
approximately one-third of TIC lesions have been observed else-
where in the tube reinforcing the need for total removal of the
tube for risk-reducing purposes (32).
From these data a plausible biological model for the pathogene-
sis of what might be a large proportion of high grade serous ovarian
carcinoma has emerged. The hypothesized pathway begins with
areas of non-neoplastic distal fallopian tubes developing TP53
mutations. The hypothesis then suggests that this leads to a non-
invasive malignancy that eventually dedifferentiates into invasive
malignancy that subsequently implants into the ovary. A prospec-
tive review of RRBSO specimens from women at high-risk of ovar-
ian cancer due to their family history or known BRCA mutations is
supportive of this hypothesis. Of 360 RRBSO specimens reviewed,
four invasive malignancies and four TICs were identified – all of
which were associated with the tubal epithelium (33).
Clearly this is a compelling theory with a persuasive, although
still incomplete, body of evidence behind it and could provide a
rationale for risk-reducing bilateral salpingectomy (RRBS). How-
ever, it may not be the only route for the pathogenesis of ovarian
cancer because the timeframe of the pathogenic process and the
point of transfer of malignant or potentially malignant tubal cells
to the ovary are not known. It is clear that even when utilizing the
FEE-SIM protocol to examine RRBSO specimens there are still
ovarian cancers identified that are not associated with any obvious
fallopian tube malignancy/pre-malignant lesion. It may be that
the tubal primary is too small to be found and/or that another,
intra-ovarian, pathway also leads to ovarian cancer and/or that
the tubal cells can be transferred to the ovary at a much earlier
time point. For example, it may be that during ovulation cortical
inclusion cysts are formed incorporating normal tubal epithelial
cells (endosalpingiosis), which can then cause carcinoma with an
underlying molecular signature consistent with the fallopian tubes
(25). If any of these additional theories are correct then high-risk
women may be done a serious disservice by neglecting to perform
an oophorectomy with salpingectomy.
The evidence supporting the tubal hypothesis of ovarian cancer
has already led to calls for bilateral salpingectomy to be added to
hysterectomies performed for benign reasons in women at aver-
age population risk of ovarian cancer. This was first proposed
in 2009 by Salvador et al (34) and has led to a 20× increase in
salpingectomy with hysterectomy in Canada (25) although there
are still barriers to its routine implementation (35–37). Adding
salpingectomy to hysterectomy does not appear to have any imme-
diate increase in complications (38). Additional proposals to per-
form salpingectomy rather than tubal ligation for women seeking
permanent contraception have also been proposed (25).
While the tubal hypothesis is an intriguing one and can be
easily integrated into routine care of women at population risk
of ovarian cancer requiring hysterectomy or contraception, is the
risk:benefit balance tipped in favor of a staged RRBS followed
by risk-reducing bilateral oophorectomy (RRBO) at a later date
in younger women at high-risk of ovarian cancer? A Canadian
group has developed a Markov Monte Carlo simulation model to
compare three strategies for risk reduction in women with BRCA
mutations: (1) RRBSO; (2) RRBS; and (3) RRBS with delayed
RRBO (18). The model estimated the number of future breast and
ovarian cancers and cardiovascular deaths attributed to prema-
ture menopause with each strategy. RRBSO was the most effective
risk-reducing strategy but RRBS with delayed RRBO was still cost
effective for those women unwilling to have a RRBSO.
Despite the evidence presented above, unfortunately the point
has not yet been reached where the tubal hypothesis of ovar-
ian cancer can be reliably used to guide decision-making around
prophylactic surgery in high-risk women (39). To safely change
current recommendations, we need prospective evidence that the
strategy of a staged approach is not inferior to upfront RRBSO. A
randomized controlled trial comparing these strategies is unfor-
tunately not feasible. The difficulties inherent in this approach are
obvious, recruiting from a highly selected group of patients will
take an international effort over many years in order to give suffi-
cient statistical power to detect a state of non-inferiority, but there
is also the ethical dilemma for clinicians offering randomization
to an untested procedure against one, which has proven mortality
benefits in a young population – would enough clinicians be in
clinical equipoise in order to recruit sufficient numbers of partic-
ipants? A prospective cohort study following high-risk women
selecting RRBS over RRBSO (risk-reducing bilateral salpingo-
oophorectomy) is a more practicable approach to answer the
question but would still require a large population to give a sta-
tistically significant result. It is unlikely that a single international
cohort study will be proposed and funded to answer this question
but there are a number of prospective cohort studies in BRCA
mutation carriers across the world that could provide the neces-
sary outcome data in the future provided the required data can be
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collected systematically. Furthermore, many familial cancer clin-
ics follow up mutation carriers and would also be in a position to
contribute prospective outcome data in the future. Provided that
all of these groups can be brought together to pool data, an answer
may be forthcoming.
So, what to advise a young BRCA mutation carrier who has
completed her family while still in her 30s, or is in her 40s and
declines RRBSO? Careful counseling is necessary to ensure that she
is fully informed about the range of surgical prevention options,
explaining the risks, and benefits, of all surgical approaches. It is
necessary to emphasize the known mortality and breast cancer
risk reduction benefits of RRBSO, and ensure that she is aware
of the range of strategies to manage any sequelae arising from a
premature surgical menopause. The advantage of the alternative
of a staged procedure starting with bilateral salpingectomy then
a bilateral oophorectomy at or approaching the age of natural
menopause is that it avoids morbidity of premature menopause
but this comes at the cost of uncertain impact on overall mortal-
ity, ovarian cancer-specific mortality and abrogation, or complete
loss of breast cancer risk reduction. The Markov model (18) con-
cluding that RRBS with delayed RRBO salpingectomy followed
by delayed oophorectomy yields the highest quality-adjusted life
expectancy (18) is intriguing, however, it is essential for a fully
informed decision that it is made clear to the high-risk woman
that no prospective data yet exists on the efficacy of bilateral salp-
ingectomy in reducing mortality in high-risk women. However, in
the end, it is a woman’s decision based on her own preferences and
life experiences and it is the role of her medical team to support
her in her choices in order to maximize their benefit and mini-
mize their risk. Some prophylactic surgery in the form of bilateral
salpingectomy is probably better than no surgery in this high-risk
population.
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